Girija Natarajan1, Seetha Shankaran2, Tracy L Nolen3, Amaanti Sridhar3, Kathleen A Kennedy4, Susan R Hintz5, Dale L Phelps6, Sara B DeMauro7, Waldemar A Carlo8, Marie G Gantz3, Abhik Das3, Rachel G Greenberg9, Noelle E Younge9, Joseph M Bliss10, Ruth Seabrook11, Pablo J Sánchez11, Myra H Wyckoff12, Edward F Bell13, Betty R Vohr10, Rosemary D Higgins14. 1. Department of Pediatrics, Wayne State University, Detroit, Michigan; gnatara@med.wayne.edu. 2. Department of Pediatrics, Wayne State University, Detroit, Michigan. 3. Social, Statistical, and Environmental Sciences Unit, RTI International, Rockville, Maryland. 4. Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas. 5. Division of Neonatal and Developmental Medicine, Department of Pediatrics, School of Medicine, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California. 6. Department of Pediatrics, University of Rochester Medical Center, Rochester, New York. 7. Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania. 8. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama. 9. Department of Pediatrics, Duke University, Durham, North Carolina. 10. Department of Pediatrics, Women and Infants Hospital of Rhode Island, Providence, Rhode Island. 11. Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital, Columbus, Ohio. 12. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas. 13. Department of Pediatrics, University of Iowa, Iowa City, Iowa; and. 14. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Abstract
OBJECTIVE: Among extremely preterm infants, we evaluated whether bevacizumab therapy compared with surgery for retinopathy of prematurity (ROP) is associated with adverse outcomes in early childhood. METHODS: This study was a retrospective analysis of prospectively collected data on preterm (22-26 + 6/7 weeks' gestational age) infants admitted to the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network centers who received bevacizumab or surgery exclusively for ROP. The primary outcome was death or severe neurodevelopmental impairment (NDI) at 18 to 26 months' corrected age (Bayley Scales of Infant and Toddler Development, Third Edition cognitive or motor composite score <70, Gross Motor Functional Classification Scale level ≥2, bilateral blindness or hearing impairment). RESULTS: The cohort (N = 405; 214 [53%] boys; median [interquartile range] gestational age: 24.6 [23.9-25.3] weeks) included 181 (45%) infants who received bevacizumab and 224 (55%) who underwent ROP surgery. Infants treated with bevacizumab had a lower median (interquartile range) birth weight (640 [541-709] vs 660 [572.5-750] g; P = .02) and longer durations of conventional ventilation (35 [21-58] vs 33 [18-49] days; P = .04) and supplemental oxygen (112 [94-120] vs 105 [84.5-120] days; P = .01). Death or severe NDI (adjusted odds ratio [aOR] 1.42; 95% confidence interval [CI] 0.94 to 2.14) and severe NDI (aOR 1.14; 95% CI 0.76 to 1.70) did not differ between groups. Odds of death (aOR 2.54 [95% CI 1.42 to 4.55]; P = .002), a cognitive score <85 (aOR 1.78 [95% CI 1.09 to 2.91]; P = .02), and a Gross Motor Functional Classification Scale level ≥2 (aOR 1.73 [95% CI 1.04 to 2.88]; P = .04) were significantly higher with bevacizumab therapy. CONCLUSIONS: In this multicenter cohort of preterm infants, ROP treatment modality was not associated with differences in death or NDI, but the bevacizumab group had higher mortality and poor cognitive outcomes in early childhood. These data reveal the need for a rigorous appraisal of ROP therapy.
OBJECTIVE: Among extremely preterm infants, we evaluated whether bevacizumab therapy compared with surgery for retinopathy of prematurity (ROP) is associated with adverse outcomes in early childhood. METHODS: This study was a retrospective analysis of prospectively collected data on preterm (22-26 + 6/7 weeks' gestational age) infants admitted to the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network centers who received bevacizumab or surgery exclusively for ROP. The primary outcome was death or severe neurodevelopmental impairment (NDI) at 18 to 26 months' corrected age (Bayley Scales of Infant and Toddler Development, Third Edition cognitive or motor composite score <70, Gross Motor Functional Classification Scale level ≥2, bilateral blindness or hearing impairment). RESULTS: The cohort (N = 405; 214 [53%] boys; median [interquartile range] gestational age: 24.6 [23.9-25.3] weeks) included 181 (45%) infants who received bevacizumab and 224 (55%) who underwent ROP surgery. Infants treated with bevacizumab had a lower median (interquartile range) birth weight (640 [541-709] vs 660 [572.5-750] g; P = .02) and longer durations of conventional ventilation (35 [21-58] vs 33 [18-49] days; P = .04) and supplemental oxygen (112 [94-120] vs 105 [84.5-120] days; P = .01). Death or severe NDI (adjusted odds ratio [aOR] 1.42; 95% confidence interval [CI] 0.94 to 2.14) and severe NDI (aOR 1.14; 95% CI 0.76 to 1.70) did not differ between groups. Odds of death (aOR 2.54 [95% CI 1.42 to 4.55]; P = .002), a cognitive score <85 (aOR 1.78 [95% CI 1.09 to 2.91]; P = .02), and a Gross Motor Functional Classification Scale level ≥2 (aOR 1.73 [95% CI 1.04 to 2.88]; P = .04) were significantly higher with bevacizumab therapy. CONCLUSIONS: In this multicenter cohort of preterm infants, ROP treatment modality was not associated with differences in death or NDI, but the bevacizumab group had higher mortality and poor cognitive outcomes in early childhood. These data reveal the need for a rigorous appraisal of ROP therapy.
Authors: Brian A Darlow; Anna L Ells; Clare E Gilbert; Glen A Gole; Graham E Quinn Journal: Arch Dis Child Fetal Neonatal Ed Date: 2011-12-30 Impact factor: 5.747
Authors: Timothy D Le Cras; Neil E Markham; Rubin M Tuder; Norbert F Voelkel; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-09 Impact factor: 5.464
Authors: María A Martínez-Castellanos; Shulamit Schwartz; Myriam L Hernández-Rojas; Veronica A Kon-Jara; Gerardo García-Aguirre; José L Guerrero-Naranjo; R V Paul Chan; Hugo Quiroz-Mercado Journal: Retina Date: 2013-02 Impact factor: 4.256
Authors: Megan M Geloneck; Alice Z Chuang; W Lloyd Clark; Michael G Hunt; Alan A Norman; Eric A Packwood; Khaled A Tawansy; Helen A Mintz-Hittner Journal: JAMA Ophthalmol Date: 2014-11 Impact factor: 7.389
Authors: A F Duncan; C Bann; C Boatman; S R Hintz; Y E Vaucher; B R Vohr; K Yolton; R J Heyne Journal: J Perinatol Date: 2015-01-29 Impact factor: 2.521
Authors: Hannes Hudalla; Thomas Bruckner; Johannes Pöschl; Thomas Strowitzki; Ruben-J Kuon Journal: Arch Gynecol Obstet Date: 2020-02-28 Impact factor: 2.344
Authors: Jane E Brumbaugh; Edward F Bell; Shawn C Hirsch; Emma G Crenshaw; Sara B DeMauro; Ira S Adams-Chapman; Jean R Lowe; Girija Natarajan; Myra H Wyckoff; Betty R Vohr; Tarah T Colaizy; Heidi M Harmon; Kristi L Watterberg; Susan R Hintz Journal: Pediatr Res Date: 2021-10-22 Impact factor: 3.756
Authors: M Elizabeth Hartnett; David K Wallace; Trevano W Dean; Zhuokai Li; Charline S Boente; Eniolami O Dosunmu; Sharon F Freedman; Richard P Golden; Lingkun Kong; S Grace Prakalapakorn; Michael X Repka; Lois E Smith; Haibo Wang; Raymond T Kraker; Susan A Cotter; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2022-04-01 Impact factor: 8.253
Authors: David K Wallace; Raymond T Kraker; Sharon F Freedman; Eric R Crouch; Amit R Bhatt; M Elizabeth Hartnett; Michael B Yang; David L Rogers; Amy K Hutchinson; Deborah K VanderVeen; Kathryn M Haider; R Michael Siatkowski; Trevano W Dean; Roy W Beck; Michael X Repka; Lois E Smith; William V Good; Lingkun Kong; Susan A Cotter; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2020-06-01 Impact factor: 7.389
Authors: Hao Tan; Patricia Blasco; Tamorah Lewis; Susan Ostmo; Michael F Chiang; John Peter Campbell Journal: Surv Ophthalmol Date: 2021-03-02 Impact factor: 6.197